Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will search for a new chief of its office just as interest in the rare disease space is increasing, particularly among large pharmaceutical companies.
Advertisement

Related Content

FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD
FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
Who's Afraid Of Big Pharma? Perhaps The Rare Disease Community
Sen. Brownback Wants FDA To Aggressively Coordinate Drug Development For Neglected/Rare Diseases
Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008

Topics

Advertisement
UsernamePublicRestriction

Register

PS072532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel